LLY · 10-Q · 2026Q2 · Full report
Acquisition / Partnership / Divestiture
ELI LILLY & Co · 2026-08-05 · Importance 71 · Surprise 60 · In source text
Lilly paid $13.3 billion during the first six months of 2026 for business development activity, primarily involving Centessa, Kelonia, Orna, Ventyx, and Ajax. In July 2026, Lilly paid approximately $2.0 billion to acquire companies for an infectious disease portfolio. Lilly also agreed to acquire AtaiBeckley Inc., subject to closing conditions, with approximately $2.8 billion potentially payable at closing. In May 2026, Lilly issued $9.0 billion of long-term debt, partly funding upfront cash consideration and related costs for the Centessa and Kelonia acquisitions.
Key facts
- The Company paid $13.3 billion in 2026 related to business development activity, primarily driven by acquisitions of Centessa, Kelonia, Orna, Ventyx, and Ajax. source
- The Company entered into an agreement to acquire AtaiBeckley Inc., subject to closing conditions, with a potential amount payable at closing of approximately $2.8 billion. source
- Acquired IPR&D charges for the three months ended June 30, 2026: $2,776 million, primarily related to the acquisitions of Orna and Ajax. source
- In July 2026, the Company paid approximately $2.0 billion to acquire companies to build an infectious disease portfolio. source
- Asset impairment, restructuring, and other special charges for the six months ended June 30, 2026 included charges related to litigation matters and accelerated vesting of employee equity awards associated with acquisitions. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -12.1% | Acquired IPR&D charges for the three months ended June 30, 2026: $2,776 million, primarily related to the acquisitions of Orna and Ajax. |
| cash | negative | realized | -9.3% | The Company paid $13.3 billion in 2026 related to business development activity, primarily driven by acquisitions of Centessa, Kelonia,… |
| assets | positive | realized | +9.3% | The Company paid $13.3 billion in 2026 related to business development activity, primarily driven by acquisitions of Centessa, Kelonia,… |
| cash | negative | realized | -1.4% | In July 2026, the Company paid approximately $2.0 billion to acquire companies to build an infectious disease portfolio. |
| assets | positive | realized | +1.4% | In July 2026, the Company paid approximately $2.0 billion to acquire companies to build an infectious disease portfolio. |
| cash | negative | probable | -1.0% | The Company entered into an agreement to acquire AtaiBeckley Inc., subject to closing conditions, with a potential amount payable at… |